文献速递精神分裂症与精神病性障碍

帕利哌酮随机停药后精神分裂症或分裂情感障碍患者精神病性复发的预测:个体参与者数据分析

Predicting psychotic relapse following randomised discontinuation of paliperidone in individuals with schizophrenia or schizoaffective disorder: an individual participant data analysis.
PubMed 文献 · Lancet Psychiatry · 2023-01-01

该个体参与者数据分析基于5项安慰剂对照的抗精神病药随机停药试验,纳入700名继续治疗和692名停药的精神分裂症或分裂情感障碍患者,使用机器学习识别复发的通用预后因素和停药特异性预测因素。结论提示应避免高剂量口服抗精神病药的突然停药,尤其对于反复住院、CGI严重度评分较高和催乳素浓度升高的个体。

要点

  • 通用预后因素包括药物阳性尿液、偏执型/紊乱型/未分化型精神分裂症、抗精神病药停药、较低社会功能、年轻年龄等。
  • 停药特异性预测因素包括催乳素浓度升高、住院次数增多和吸烟。

核心结论

  • 常规可用的精神病性复发通用预后因素和停药特异性预测因素可用于支持个体化治疗。
  • 应避免高剂量口服抗精神病药的突然停药,尤其对于反复住院、CGI严重度评分较高和催乳素浓度升高的个体,以降低复发风险。

研究设计与样本

  • 个体参与者数据分析,检索Yale University Open Data Access Project数据库中的安慰剂对照、随机抗精神病药停药试验。
  • 纳入5项试验,继续治疗组700名参与者(304名女性,396名男性),停药组692名参与者(292名女性,400名男性),中位年龄分别为37岁(IQR 28-47)和38岁(IQR 28-47)。
  • 评估36个预设基线变量,使用单变量和多变量比例风险回归模型(包括多变量治疗组与变量交互作用)及机器学习分类变量。

主要发现

  • 通用预后因素中增加复发风险的有:药物阳性尿液;偏执型、紊乱型和未分化型精神分裂症(分裂情感障碍风险较低);精神科和神经科不良事件;静坐不能严重度较高;抗精神病药停药;较低社会功能;年轻年龄;较低肾小球滤过率;苯二氮䓬类合并用药(抗癫痫药合并用药风险较低)。
  • 停药特异性预测因素中增加风险的有:催乳素浓度升高、住院次数增多和吸烟。
  • 既是通用预后因素又是停药后增加风险的预测因素有:口服抗精神病药治疗(长效针剂风险较低)、抗精神病药研究药物末次剂量较高、抗精神病药治疗持续时间较短、CGI严重度评分较高。

关键数值与推荐

  • 通用预后因素包括药物阳性尿液、特定精神分裂症类型、精神科和神经科不良事件、静坐不能严重度较高、抗精神病药停药、较低社会功能、年轻年龄、较低肾小球滤过率、苯二氮䓬类合并用药等。
  • 停药特异性预测因素包括催乳素浓度升高、住院次数增多和吸烟。
  • 同时为预后因素和停药后预测因素包括口服抗精神病药治疗、末次剂量较高、治疗持续时间较短和CGI严重度评分较高。

临床怎么用

  • 可利用常规可用的预后因素和停药特异性预测因素支持个体化治疗决策。
  • 对于反复住院、CGI严重度评分较高和催乳素浓度升高的个体,应避免高剂量口服抗精神病药的突然停药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Predicting relapse for individuals with psychotic disorders is not well established, especially after discontinuation of antipsychotic treatment. We aimed to identify general prognostic factors of relapse for all participants (irrespective of treatment continuation or discontinuation) and specific predictors of relapse for treatment discontinuation, using machine learning. METHODS: For this individual participant data analysis, we searched the Yale University Open Data Access Project's database for placebo-controlled, randomised antipsychotic discontinuation trials with participants with schizophrenia or schizoaffective disorder (aged ≥18 years). We included studies in which participants were treated with any antipsychotic study drug and randomly assigned to continue the same antipsychotic drug or to discontinue it and receive placebo. We assessed 36 prespecified baseline variables at randomisation to predict time to relapse, using univariate and multivariate proportional hazard regression models (including multivariate treatment group by variable interactions) with machine learning to categorise the variables as general prognostic factors of relapse, specific predictors of relapse, or both. FINDINGS: We identified 414 trials, of which five trials with 700 participants (304 [43%] women and 396 [57%] men) were eligible for the continuation group and 692 participants (292 [42%] women and 400 [58%] men) were eligible for the discontinuation group (median age 37 [IQR 28-47] years for continuation group and 38 [28-47] years for discontinuation group). Out of the 36 baseline variables, general prognostic factors of increased risk of relapse for all participants were drug-positive urine; paranoid, disorganised, and undifferentiated types of schizophrenia (lower risk for schizoaffective disorder); psychiatric and neurological adverse events; higher severity of akathisia (ie, difficulty or inability to sit still); antipsychotic discontinuation; lower social performance; younger age; lower glomerular filtration rate; benzodiazepine comedication (lower risk for anti-epileptic comedication). Out of the 36 baseline variables, predictors of increased risk specifically after antipsychotic discontinuation were increased prolactin concentration, higher number of hospitalisations, and smoking. Both prognostic factors and predictors with increased risk after discontinuation were oral antipsychotic treatment (lower risk for long-acting injectables), higher last dosage of the antipsychotic study drug, shorter duration of antipsychotic treatment, and higher score on the Clinical Global Impression (CGI) severity scale The predictive performance (concordance index) for participants who were not used to train the model was 0·707 (chance level is 0·5). INTERPRETATION: Routinely available general prognostic factors of psychotic relapse and predictors specific for treatment discontinuation could be used to support personalised treatment. Abrupt discontinuation of higher dosages of oral antipsychotics, especially for individuals with recurring hospitalisations, higher scores on the CGI severity scale, and increased prolactin concentrations, should be avoided to reduce the risk of relapse. FUNDING: German Research Foundation and Berlin Institute of Health.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Brandt L, Ritter K, Schneider-Thoma J, et al. Predicting psychotic relapse following randomised discontinuation of paliperidone in individuals with schizophrenia or schizoaffective disorder: an individual participant data analysis. Lancet Psychiatry. 2023. PMID: 36804071. doi:10.1016/S2215-0366(23)00008-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。